Pulse Biosciences (PLSE) Competitors $17.57 +0.28 (+1.62%) Closing price 04:00 PM EasternExtended Trading$17.60 +0.02 (+0.14%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PLSE vs. GKOS, TMDX, NVST, SLNO, LIVN, WRBY, EYE, INSP, PRCT, and LMATShould you be buying Pulse Biosciences stock or one of its competitors? The main competitors of Pulse Biosciences include Glaukos (GKOS), TransMedics Group (TMDX), Envista (NVST), Soleno Therapeutics (SLNO), LivaNova (LIVN), Warby Parker (WRBY), National Vision (EYE), Inspire Medical Systems (INSP), PROCEPT BioRobotics (PRCT), and LeMaitre Vascular (LMAT). These companies are all part of the "medical equipment" industry. Pulse Biosciences vs. Its Competitors Glaukos TransMedics Group Envista Soleno Therapeutics LivaNova Warby Parker National Vision Inspire Medical Systems PROCEPT BioRobotics LeMaitre Vascular Glaukos (NYSE:GKOS) and Pulse Biosciences (NASDAQ:PLSE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk. Which has more volatility & risk, GKOS or PLSE? Glaukos has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.79, meaning that its stock price is 79% more volatile than the S&P 500. Which has better earnings & valuation, GKOS or PLSE? Pulse Biosciences has lower revenue, but higher earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlaukos$383.48M12.76-$146.37M-$1.65-51.72Pulse Biosciences$700K1,689.23-$53.58M-$1.05-16.73 Do institutionals and insiders hold more shares of GKOS or PLSE? 99.0% of Glaukos shares are held by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are held by institutional investors. 5.8% of Glaukos shares are held by insiders. Comparatively, 74.6% of Pulse Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is GKOS or PLSE more profitable? Pulse Biosciences has a net margin of 0.00% compared to Glaukos' net margin of -21.43%. Glaukos' return on equity of -8.59% beat Pulse Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Glaukos-21.43% -8.59% -6.61% Pulse Biosciences N/A -63.19%-54.98% Does the media prefer GKOS or PLSE? In the previous week, Glaukos had 4 more articles in the media than Pulse Biosciences. MarketBeat recorded 8 mentions for Glaukos and 4 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 0.92 beat Glaukos' score of 0.12 indicating that Pulse Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Pulse Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer GKOS or PLSE? Glaukos presently has a consensus price target of $116.92, suggesting a potential upside of 37.01%. Pulse Biosciences has a consensus price target of $22.00, suggesting a potential upside of 25.21%. Given Glaukos' stronger consensus rating and higher probable upside, equities analysts plainly believe Glaukos is more favorable than Pulse Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Glaukos 2 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.69Pulse Biosciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryGlaukos beats Pulse Biosciences on 9 of the 17 factors compared between the two stocks. Get Pulse Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PLSE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLSE vs. The Competition Export to ExcelMetricPulse BiosciencesMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.18B$7.05B$6.13B$10.47BDividend YieldN/A1.18%5.73%4.78%P/E Ratio-16.7327.5185.1527.20Price / Sales1,689.2328.38575.35178.82Price / CashN/A21.7037.3961.86Price / Book9.405.1812.396.65Net Income-$53.58M$179.79M$3.32B$276.79M7 Day Performance-8.73%-3.11%-0.24%-1.51%1 Month Performance5.59%4.60%9.56%5.45%1 Year Performance1.04%3.33%71.67%36.24% Pulse Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLSEPulse Biosciences4.0488 of 5 stars$17.57+1.6%$22.00+25.2%+5.5%$1.16B$700K0.00140GKOSGlaukos4.3199 of 5 stars$86.64-0.9%$122.00+40.8%-33.1%$5.01B$383.48M-52.51780Analyst ForecastTMDXTransMedics Group3.3067 of 5 stars$113.93-1.5%$125.40+10.1%-14.6%$3.88B$531.29M59.03210Positive NewsAnalyst ForecastNVSTEnvista4.3094 of 5 stars$20.64-1.0%$20.92+1.4%+10.6%$3.43B$2.55B64.5012,300News CoverageAnalyst RevisionSLNOSoleno Therapeutics4.2228 of 5 stars$58.45-1.3%$115.09+96.9%+25.0%$3.15B$32.66M-14.1230LIVNLivaNova2.7824 of 5 stars$52.63-1.4%$59.71+13.5%-0.3%$2.91B$1.31B-13.532,900WRBYWarby Parker2.6363 of 5 stars$25.41-3.1%$24.75-2.6%+42.7%$2.76B$771.32M-362.953,780EYENational Vision2.4642 of 5 stars$28.15-2.5%$24.73-12.2%+163.8%$2.29B$1.89B-156.3913,411Positive NewsINSPInspire Medical Systems4.8946 of 5 stars$76.36-0.3%$154.43+102.2%-60.3%$2.26B$861.31M44.141,246News CoverageAnalyst ForecastAnalyst RevisionPRCTPROCEPT BioRobotics2.6693 of 5 stars$35.24-2.0%$70.00+98.6%-53.2%$2.00B$224.50M-22.74430Trending NewsAnalyst ForecastAnalyst RevisionLMATLeMaitre Vascular3.7424 of 5 stars$87.49-0.4%$97.60+11.6%-4.4%$1.99B$219.86M42.47490News CoverageAnalyst Forecast Related Companies and Tools Related Companies GKOS Competitors TMDX Competitors NVST Competitors SLNO Competitors LIVN Competitors WRBY Competitors EYE Competitors INSP Competitors PRCT Competitors LMAT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLSE) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredWall St’s “AI Godfather” breaks his silenceWhats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.Chaikin Analytics | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredThis dark force is about to change everythingTwo Nobel Prize winners warn of this once-in-a-generation wealth shift…THE FINAL DISPLACEMENT An unstoppabl...Porter & Company | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulse Biosciences, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulse Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
